Navidea Biopharmaceuticals Inc. (AMEX:NAVB) Relative Strength Index (RSI) is 63.60, with weekly volatility at 9.79% and ATR at 0.12. The NAVB stock’s 52-week price range has touched low of $1.18 and a $5.36 high. Intraday shares traded counted 0.37 million, which was -61.38% lower than its 30-day average trading volume of 228.16K. Its shares traded higher over the last trading session, gaining 12.50% on 05/20/21. The shares fell to a low of $1.64 before closing at $1.89. NAVB’s previous close was $1.68 while the outstanding shares total 28.07M. The firm has a beta of 1.77.
Investors have identified the Biotechnology company Navidea Biopharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $52.69 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Navidea Biopharmaceuticals Inc. (NAVB) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 8.83 million total, with 4.16 million as their total liabilities.
NAVB were able to record -3.06 million as free cash flow during the 08/11/2021 quarter of the year, this saw their quarterly net cash flow reduce by 4.84 million. In cash movements, the company had a total of -3.06 million as operating cash flow.
Potential earnings growth for Navidea Biopharmaceuticals Inc. (NAVB)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/11/2021 quarter of the year, Navidea Biopharmaceuticals Inc. recorded a total of 0.12 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with -25.81% coming in sequential stages and their sales for the 08/11/2021 quarter reducing by -76.61%.
Having a look at the company’s valuation, the company is expected to record -0.26 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on NAVB sounds very interesting.
Is the stock of NAVB attractive?
In related news, Director, Witter Malcolm G bought 10,000 shares of the company’s stock in a transaction that recorded on Apr 23. The purchase was performed at an average price of 1.60, for a total value of 16,000. As the purchase deal closes, the Director, Witter Malcolm G now bought 21,500 shares of the company’s stock, valued at 44,505. Also, Director, Witter Malcolm G bought 15,000 shares of the company’s stock in a deal that was recorded on Mar 03. The shares were cost at an average price of 2.31 per share, with a total market value of 34,650. Following this completion of disposal, the Director, Witter Malcolm G now holds 5,000 shares of the company’s stock, valued at 10,350. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.40%.